Targeting the Fas/Fas ligand pathway in cancer
Authors:
- Ken NallyKNKen Nally
- Raymond G KellyRKRaymond G Kelly
- Terrence M O’connorTOTerrence M O’connor
- Fergus ShanahanFSFergus Shanahan
- Joe O’connellJOJoe O’connell
- 27 September 2005
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 9 (5) , 1031-1044
Abstract
Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (FasL). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.Keywords
This publication has 95 references indexed in Scilit:
- In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancerCancer Gene Therapy, 2004
- The death-inducing signalling complex is recruited to lipid rafts in Fas-induced apoptosisBiochemical and Biophysical Research Communications, 2002
- STAT-1-Independent Upregulation of FADD and Procaspase-3 and -8 in Cancer Cells Treated with Cytotoxic DrugsBiochemical and Biophysical Research Communications, 1999
- Activation of the CD95 (APO-1/Fas) pathway in drug- and γ-irradiation-induced apoptosis of brain tumor cellsCell Death & Differentiation, 1998
- The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosisCell Death & Differentiation, 1998
- Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivoEuropean Journal of Immunology, 1995
- Fas(CD95)/FasL interactions required for programmed cell death after T-cell activationNature, 1995
- Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomasNature, 1995
- Fas and Fas ligand: lpr and gld mutationsImmunology Today, 1995
- Molecular cloning and expression of the fas ligand, a novel member of the tumor necrosis factor familyCell, 1993